EMA names Sepodes CHMP chair, Bell leaving Valo as CEO, and more
Plus: Autolus hires Matthias Will as CDO, and updates from HotSpot, Prilenia, Frazier, BIA and BioCentriq
Bruno Sepodes will begin a three-year stint as chair of EMA’s human medicines committee on Sept. 21, following his election to the position by the agency’s CHMP. Sepodes has worked with EMA for over 16 years, most recently as a member and vice-chair of CHMP, and co-chair of EMA’s emergency task force. He is also a professor of pharmacological sciences at the University of Lisbon and an honorary senior lecturer at Queen Mary University of London.
Graeme Bell disclosed on LinkedIn his departure from Valo Health Inc., where he was interim CEO. Bell joined Valo in 2020 as EVP, CFO & CPO, becoming EVP, COO & CFO in 2023 and interim CEO in January. Top-line results from the company’s Phase II trial of OPL-0401, a small molecule targeting ROCK1 and 2 to treat diabetic retinopathy, are expected by Dec. 31. ...